Analysts Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $9.33

Esperion Therapeutics, Inc. (NASDAQ:ESPR) has been given an average recommendation of “Hold” by the five ratings firms that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $9.33.

Several equities analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Monday, March 25th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Esperion Therapeutics in a report on Wednesday, April 10th. Finally, Bank of America lowered Esperion Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 3rd.

Institutional Investors Weigh In On Esperion Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ESPR. Simplicity Solutions LLC purchased a new stake in Esperion Therapeutics during the third quarter valued at about $30,000. Pinnacle Associates Ltd. raised its position in Esperion Therapeutics by 15.7% during the third quarter. Pinnacle Associates Ltd. now owns 289,123 shares of the biopharmaceutical company’s stock valued at $283,000 after purchasing an additional 39,285 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new stake in Esperion Therapeutics during the third quarter valued at about $29,000. Jacob Asset Management of New York LLC purchased a new stake in Esperion Therapeutics during the third quarter valued at about $59,000. Finally, Monaco Asset Management SAM raised its position in Esperion Therapeutics by 68.5% during the third quarter. Monaco Asset Management SAM now owns 1,171,779 shares of the biopharmaceutical company’s stock valued at $1,148,000 after purchasing an additional 476,477 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Stock Performance

ESPR stock opened at $1.91 on Friday. The stock’s 50 day simple moving average is $2.45 and its 200 day simple moving average is $1.97. Esperion Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $3.40. The company has a market cap of $361.75 million, a P/E ratio of -0.90 and a beta of 0.84.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The firm had revenue of $32.25 million for the quarter, compared to analyst estimates of $26.84 million. During the same period last year, the company posted ($0.76) earnings per share. Equities analysts predict that Esperion Therapeutics will post -0.68 earnings per share for the current year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.